No Data
No Data
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ram Selvaraju maintains $Genmab(GMAB.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 41.2% and a
Strong Buy on Genmab: Robust DARZALEX Sales and Promising Pipeline Drive Positive Outlook
Express News | HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
TD Cowen Keeps Their Hold Rating on Genmab (GMAB)
Genmab A/S (0MGB) Receives a Buy From Barclays
J&J Beats in Q2 as Pharma Segment Outperforms
No Data